3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
81
Leukemia
41
Gastrointestinal Stromal Tumors
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Leukemia, Myeloid, Chronic-Phase
27
Blast Crisis
13
Neoplasms
10
Neoplasm Metastasis
10
Melanoma
10
Brain Neoplasms
10
Lung Neoplasms
9
Prostatic Neoplasms
8
Leukemia, Myeloid, Acute
8
Gliosarcoma
8
Glioblastoma
8
Leukemia, Myeloid, Accelerated Phase
7
Glioma
6
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
5
Philadelphia Chromosome
5
Oligodendroglioma
5
Recurrence
4
Primary Myelofibrosis
4
Polycythemia Vera
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Central Nervous System Neoplasms
4
Breast Neoplasms
4
Astrocytoma
4
Interventions
Ipilimumab
17
Nivolumab
15
incomplete Freund's adjuvant
8
Cyclophosphamide
7
CTLA-4 Antigen
7
pembrolizumab
6
Ranibizumab
6
sargramostim
5
Radiosurgery
5
Blood Specimen Collection
5
tebentafusp
4
Temozolomide
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
MART-1 Antigen
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
fludarabine
3
aflibercept
3
Thalidomide
3
Sunitinib
3
Specimen Handling
3
MAGEA3 protein, human
3
Interleukin-2
3
130-nm albumin-bound paclitaxel
3
relatlimab
2
olaparib
2
montanide ISA 51
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uveal Melanoma
×
Imatinib Mesylate
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled